a healthcare provider may recommend them once a month or even quarterly, depending on individual needs
Dihydroergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions and rare reports of ergotism have been obtained from patients treated with dihydroergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated with dihydroergotamine and protease inhibitors (e.g., ritonavir), presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (see CONTRAINDICATIONS)
This is not an arbitrary number
This makes injured tissue more sensitive to circulating growth factors, amplifying the repair signal without requiring additional hormone supplementation
This systemic approach has been noted to be effective for diverse injuries, including gastrointestinal issues 5
I also see brands expanding the peptide category by developing multi-peptide formulations, hydration-focused systems, and even scalp care products that incorporate peptide technology
